MSGS Stock Today: March 9 — 13F Filings Flag Stake Cuts, Bullish PTs

MSGS stock is in focus after fresh 13F updates showed notable hedge fund stake cuts alongside upbeat analyst views. We break down what this means for MSGS and MSGS stock today for Australian investors. Recent data show shares at US$313.34 (5 Mar 2025), up 21.15% year to date and 58.10% over 12 months. With Q3 filings flagging Quantbot and Gamco reductions, yet seven Buy ratings versus two Holds, investors face a mixed setup ahead of the next earnings date on 1 May 2026 (UTC).

13F updates: stake cuts vs. bullish research

Quantbot Technologies reduced its position by 52% while Gamco Investors trimmed 1.3%, according to recent Q3 disclosures. These updates were highlighted by MarketBeat for both Gamco and Quantbot source and source. Although ownership shifts are not real time, they can sway near-term sentiment in MSGS stock as traders react to headline positioning.

13F filings MSGS provide a backward look, but they often influence the marginal bid. With daily volume at 156,411 versus a 233,026 average, liquidity remains steady but thinner than usual. Hedge fund stake cuts can dampen dip-buying interest, even if temporary. For MSGS stock, we think flow sensitivity rises around key technical levels and during news bursts tied to team performance.

Despite hedge fund stake cuts, coverage skews positive: seven Buy ratings and two Holds, implying a Buy consensus. While specific analyst price targets were not in our feed, commentary remains constructive on assets like the Knicks and Rangers. That backdrop can counterbalance ownership headlines and support MSGS stock on weakness, especially if fundamentals or upcoming catalysts surprise to the upside.

Price action and technical setup

The tape still trends higher. Price sits above the 50-day (US$286.58) and 200-day (US$229.27) moving averages, with ADX at 42.57 signaling a strong trend. RSI at 55.74 is neutral, while MACD’s histogram is slightly negative (−1.23), hinting at a pause. For MSGS stock, that reads as constructive momentum with a modest consolidation bias in the short run.

Price is near the Bollinger middle band (US$308.96) and above the Keltner middle (US$310.68). The upper Bollinger band near US$349.50 marks resistance, with US$268.42 as lower support. Average True Range sits at 11.19, so we expect wider swings into catalysts. For MSGS stock, traders may anchor around the US$308–US$311 area for near-term balance.

MSGS stock has advanced 21.15% YTD and 58.10% over one year, with 3-month gains of 38.95% and 6-month gains of 60.03%. The latest session showed US$313.34, down 1.56% on the day, on 156,411 shares versus a 233,026 average. The setup implies strength on higher time frames, with short-term pullbacks being tested against trend support.

Valuation and risk checks for Australian investors

Earnings remain negative (EPS −0.68; P/E not meaningful), while revenue multiples are rich (EV/Sales 8.87; Price/Sales 7.06). Liquidity is tight (current ratio 0.47) and interest coverage low (0.21), pointing to balance sheet risk if cash flows soften. These factors argue for measured sizing when considering MSGS stock, especially around macro or team-related revenue shocks.

Our models are split: a B+ Stock Grade with a BUY tilt contrasts with a separate C− “Strong Sell” company rating that flags weak ROA, leverage, and valuation. The difference reflects momentum and relative performance versus core fundamentals. For MSGS stock, we see a momentum-fundamental tension that can resolve either with improved earnings or a multiple reset.

Australian buyers should factor FX conversion into returns and risk, given shares trade in US dollars. Execution typically occurs via global brokerage platforms during US market hours. There is no current dividend, so income appeal is limited. For MSGS stock, consider costs, spreads, and currency exposure, then reassess position size around earnings windows and playoff-related news.

What to watch next: catalysts and positioning

The next earnings announcement is scheduled for 1 May 2026 (UTC). We will watch for revenue trajectory, expense discipline, and any commentary on media rights or sponsorships. A credible path toward sustained profitability could justify premium multiples. MSGS stock tends to react strongly to guidance shifts, so risk controls into the print make sense.

Keep monitoring quarterly 13F filings MSGS and any Form 4 insider transactions for signals on incremental supply or confidence. While 13Fs lag, repeated trims or additions can still steer sentiment. For MSGS stock, clustering of buys or sells across institutions often aligns with breakouts or failed rallies, especially near key technical zones.

Playoff runs by the Knicks or Rangers can lift ticketing, merchandise, and sponsorship revenue. Media rights updates and arena-related activations also matter. Australian fans following the NBA and NHL may see headlines translate into trading interest. We think MSGS stock remains sensitive to team momentum, particularly late-season outcomes and postseason visibility.

Final Thoughts

We see a constructive but mixed picture. Q3 13F updates show selected hedge fund stake cuts, yet analysts remain broadly positive with seven Buys and two Holds. Technically, price trends strong above key moving averages with neutral momentum readings, while volatility stays elevated into catalysts. Valuation looks full against negative EPS and tight liquidity, so sizing and risk controls matter. For Australian investors, currency exposure, execution costs, and US trading hours add extra layers. Into the 1 May 2026 earnings date, MSGS stock may lean on trend support, with direction likely set by guidance quality and any postseason tailwinds from the Knicks or Rangers.

FAQs

Disclaimer:

The content shared by Meyka AI PTY LTD is solely for research and informational purposes.  Meyka is not a financial advisory service, and the information provided should not be considered investment or trading advice.